EMA committee recommends market withdrawal of obesity drug

Obesity drug amfepramone is not used as it was intended and can cause serious side effects, which is why the European Medicines Agency’s risk assessment committee recommends market authorizations be withdrawn.
Photo: Rob Acket/EMA
Photo: Rob Acket/EMA
by christian bundgaard, translated by daniel pedersen

Studies from both Denmark and Germany have made the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommend that obesity drugs containing amfepramone be withdrawn from the market, the committee reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading